TPN and HPN Negligence: When Do Parenteral Nutrition Errors Become Legally Significant?

Total parenteral nutrition (TPN) and home parenteral nutrition (HPN) are among the most complex and high-risk nutritional interventions in clinical practice. They are used in patients whose gastrointestinal tract cannot support adequate enteral or oral nutrition: those with intestinal failure, short bowel syndrome, Crohn's disease with extensive resection, radiation enteritis, and other conditions that eliminate the gut as a viable route for nutritional support.

When TPN or HPN management fails, the consequences can be catastrophic. Refeeding syndrome, catheter-related bloodstream infection, electrolyte disturbances causing cardiac arrhythmia, liver disease secondary to long-term PN, and metabolic bone disease are all recognised complications of inadequate management. As a dietitian expert witness, I have been instructed in cases where these complications arose in the context of failures that were foreseeable and preventable.

The Clinical Complexity of PN Management

Parenteral nutrition is not a set-and-forget intervention. It requires precise calculation of macronutrient and micronutrient requirements, which change with the patient's clinical status. It requires regular biochemical monitoring: glucose, electrolytes, liver function, phosphate, magnesium, and trace elements. It requires clinical review at intervals defined by the patient's clinical stability and route of administration. And it requires a multidisciplinary nutrition support team capable of responding when monitoring reveals abnormalities.

NICE CG32 sets out the standard for parenteral nutrition in clinical settings: patients should be managed by a multidisciplinary nutrition support team where possible; biochemical monitoring should occur at the frequency determined by the patient's clinical stability; and complications should be recognised and managed in a timely manner. ESPEN guidelines and BAPEN/BIFA monitoring guidance add further specificity for particular patient groups and clinical scenarios.

Prescribing and Initiation Errors: Refeeding Syndrome

The most clinically serious errors in TPN initiation relate to refeeding syndrome. Patients who are severely malnourished before PN is commenced are at high risk of hypophosphataemia, hypomagnesaemia, and hypokalaemia during feeding, driven by the insulin-mediated cellular uptake of electrolytes that occurs when carbohydrate is reintroduced. These disturbances can cause cardiac arrhythmia, respiratory failure, and death.

NICE CG32 requires that refeeding risk be assessed before PN commences, that high-risk patients receive thiamine supplementation and corrected electrolyte replacement before or simultaneously with feeding, and that feeding commence at a reduced rate with careful escalation. Where these steps are not taken and refeeding syndrome causes harm, the failure to follow the established clinical pathway is identifiable and assessable.

Monitoring Failures During PN

Inadequate biochemical monitoring during PN is the most common failure pattern in the cases I review. A patient commenced on PN whose electrolytes are not checked with sufficient frequency, whose glucose is not monitored, and whose phosphate and magnesium trends are not reviewed is being managed at significant risk. Abnormalities that would have been detected and corrected with appropriate monitoring can cause serious harm when missed.

In one recurring class of case, a patient on TPN develops deteriorating liver function secondary to long-term PN administration. Liver enzyme monitoring was undertaken but not reviewed or acted upon by anyone with the clinical knowledge to recognise the pattern. PN-associated liver disease (PNALD) is a recognised complication with known risk factors and established management strategies. Identifying it requires someone to be looking for it, at the right frequency, and responding when the findings indicate concern.

HPN-Specific Issues: Community Management and Continuity

Home parenteral nutrition raises distinct issues relating to continuity of care, monitoring in the community, and the management of acute deterioration. HPN patients are dependent on their PN bag for the majority of their hydration and nutritional needs. When PN supply is disrupted — through a logistical failure, a change in prescribing, or a hospital admission that alters the feeding regime without adequate handover — the consequences for the patient can be severe and rapid.

I have been instructed in cases where HPN supply was disrupted during a period of clinical transition, where the communication between the specialist PN service and the admitting hospital was inadequate, and where the patient suffered a serious and preventable deterioration as a result. The expert's role is to establish what the transition plan should have looked like, whether the responsible clinical teams met the standard of care required, and what the clinical consequences of the failure were.

Practical Guidance for Instructing Solicitors

Records to obtain: PN prescribing records and formulation sheets for the relevant period; biochemical monitoring results including electrolytes, glucose, liver function, phosphate, magnesium, trace elements, and full blood count; nutrition support team clinical notes; correspondence between PN service and referring team or GP; any HPN service documentation including bag delivery records and monitoring visit notes.

Key instruction questions: Was refeeding risk assessed and managed appropriately before PN initiation? Was biochemical monitoring undertaken at the frequency required by the patient's clinical status and national guidelines? Were identified abnormalities acted upon in a timely manner? Did failures in PN management cause or materially contribute to the harm alleged?